Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Triple-negative breast cancer (TNBC) is cancer that tested as negative for estrogen
receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor …

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are
active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study …

Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is
estimated that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone …

Drug candidates that form covalent linkages with their target proteins have been
underexplored compared with the conventional counterparts that modulate biological …

Patients with breast cancer along with metastatic estrogen and progesterone receptor
(ER/PR)-and human epidermal growth factor receptor 2 (HER2)-negative tumors are …

Cancer-specific DNA repair defects are abundant in malignant tissue and present an
opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data …

Purpose: To evaluate the preclinical pharmacokinetics and antitumor efficacy of a novel
orally bioavailable poly (ADP-ribose) polymerase (PARP) inhibitor, ABT-888. Experimental …

Poly (ADP-ribose) polymerase activation is an immediate cellular response to metabolic-,
chemical-, or ionizing radiation-induced DNA damage and represents a new target for …

Historically, PARP inhibitors (PARPi) were developed to potentiate the cytotoxic effect of
certain chemotherapeutic agents and are currently being investigated in combination with …